The therapeutic drug monitoring market size has grown rapidly in recent years. It will grow from $2.41 billion in 2025 to $2.67 billion in 2026 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to increasing use of narrow therapeutic index drugs, expansion of hospital laboratory testing, adoption of immunoassay technologies, rising prevalence of chronic diseases, improvements in analytical instrumentation.
The therapeutic drug monitoring market size is expected to see rapid growth in the next few years. It will grow to $4.09 billion in 2030 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to growing demand for precision medicine, expansion of automated diagnostic laboratories, increasing focus on patient-specific dosing, advancements in mass spectrometry technologies, rising adoption of real-time therapeutic monitoring. Major trends in the forecast period include increasing adoption of lc-ms based monitoring techniques, rising use of personalized medicine approaches, growing integration of automated laboratory systems, expansion of real-time drug level analysis, enhanced focus on precision dosing.
The rising use of drugs is expected to drive growth in the therapeutic drug monitoring market in the coming years. Drugs are substances used for medical purposes to diagnose, treat, or prevent diseases in humans or animals. Therapeutic drug monitoring helps optimize drug dosage by measuring and adjusting drug concentrations in the bloodstream, ensuring effectiveness while minimizing side effects. For example, in January 2024, the Office for Health Improvement & Disparities, a UK-based government department, reported that between April 2022 and March 2023, 12,418 young people under 18 engaged with alcohol and drug services, marking a 10% increase from 11,326 cases the previous year. Thus, the rising use of drugs is fueling growth in the therapeutic drug monitoring market.
Major companies in the therapeutic drug monitoring market are concentrating on developing anti-idiotypic antibody technology to improve the sensitivity and specificity of assays for accurately measuring biologic drug levels and evaluating patient immune responses. This technology is instrumental in therapeutic drug monitoring as it allows for precise detection and measurement of biologic drug levels, ensuring accurate dosing and effective tracking of patient immune responses. For example, in June 2024, Bio-Rad Laboratories, a U.S.-based biotechnology company, introduced new anti-idiotypic and anti-monomethyl auristatin E (MMAE) antibodies designed for bioanalytical assays, enhancing pharmacokinetic (PK) and antidrug-antibody (ADA) monitoring. These innovative antibodies improve the reliability of assays for antibody-drug conjugates (ADCs) and play a crucial role in the therapeutic drug monitoring market by enabling accurate assessments of drug levels and immune responses, ultimately facilitating optimal patient dosing.
In February 2023, Sentinel Diagnostics, an Italian in vitro diagnostic company, completed the acquisition of Eureka S.r.l. for an undisclosed amount. This strategic move positions Sentinel Diagnostics to emerge as a significant producer and developer of IVD tests. The expanded capabilities resulting from this acquisition will empower Sentinel Diagnostics to offer clinical laboratories a broader selection of assays, spanning from high-throughput core lab tests to the most cutting-edge, specialized second-level assays. EUREKA S.r.l. is an Italian IVD chromatographic company providing ready-to-use diagnostic kits for HPLC, GC, GC-MS, and LC-MS/MS applications, serving special clinical chemistry, therapeutic drug monitoring, occupational toxicology, and forensic toxicology purposes.
Major companies operating in the therapeutic drug monitoring market are Abbott Laboratories Inc., F. Hoffmann-La Roche AG, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Sekisui Medical Co., Buehlmann Laboratories AG, Danaher Corporation, Bio-Rad Laboratories Inc., bioMérieux SA, Randox Laboratories Limited, Chromsystems Instruments & Chemicals GmbH, Grifols SA, Merck KGaA, BioChem Pharmaceuticals, Beckman Coulter Inc., DiaSorin S.p.A., Hologic Inc., Immunodiagnostic Systems Holdings plc, Kronus Inc., QuidelOrtho Corporation, Sysmex Corporation, TDM Solutions Inc., Theradiag, Tosoh Bioscience LLC, Trinity Biotech plc, Associated Regional and University Pathologists Inc., Mayo Clinic Laboratories, Quest Diagnostics.
North America was the largest region in the therapeutic drug monitoring market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global therapeutic drug monitoring market report during the forecast period. The regions covered in the therapeutic drug monitoring market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the therapeutic drug monitoring market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the therapeutic drug monitoring market by increasing costs of imported analyzers, reagents, chromatography systems, mass spectrometers, and electronic components used in laboratory diagnostics. Hospital and commercial laboratories in North America and Europe are most affected due to reliance on imported analytical equipment, while Asia-Pacific faces higher costs for exported instruments. These tariffs are raising testing costs and slowing equipment upgrades. However, they are also encouraging local manufacturing, regional reagent production, and investment in domestic diagnostic capabilities.
The therapeutic drug monitoring market research report is one of a series of new reports that provides therapeutic drug monitoring market statistics, including therapeutic drug monitoring industry global market size, regional shares, competitors with a therapeutic drug monitoring market share, detailed therapeutic drug monitoring market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic drug monitoring industry. This therapeutic drug monitoring market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Therapeutic drug monitoring (TDM) is a clinical procedure that involves continuous monitoring of a patient's bloodstream to assess the concentration of a specific medicine, ensuring the effectiveness of their dose regimens. TDM is employed for pharmaceuticals that have challenging target concentrations to monitor, medications exhibiting significant pharmacokinetic variability, drugs with established therapeutic effects and notable side effects, and medications with narrow therapeutic ranges.
The primary product types within therapeutic drug monitoring encompass consumables, equipment, immunoassay analyzers, chromatography, and detectors. Consumables for therapeutic drug monitoring include reagents and supplies utilized alongside TDM assays. Various technologies are employed, such as immunoassays, chemiluminescence immunoassays, colorimetric immunoassays, fluorescence immunoassays, radioimmunoassay, other immunoassays, chromatography-ms, lc-ms, and gc-mc. These technologies cover different drug classes, including antiseptic drugs, antibiotic drugs, immunosuppressant drugs, antiarrhythmic drugs, bronchodilator drugs, psychoactive drugs, and other drugs. Therapeutic drug monitoring is applicable in diverse settings, including hospital laboratories, commercial and private laboratories, and other end-users.
The therapeutic drug monitoring market includes revenues earned by entities by providing drug monitoring, urine drug testing, drug efficacy testing, and drug toxicology. The market value includes the value of related goods sold by the service provider or included within the service offering. The therapeutic drug monitoring market also includes sales of Immunoassay kits, Mass spectrometry instruments, and Chromatography systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The therapeutic drug monitoring market size is expected to see rapid growth in the next few years. It will grow to $4.09 billion in 2030 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to growing demand for precision medicine, expansion of automated diagnostic laboratories, increasing focus on patient-specific dosing, advancements in mass spectrometry technologies, rising adoption of real-time therapeutic monitoring. Major trends in the forecast period include increasing adoption of lc-ms based monitoring techniques, rising use of personalized medicine approaches, growing integration of automated laboratory systems, expansion of real-time drug level analysis, enhanced focus on precision dosing.
The rising use of drugs is expected to drive growth in the therapeutic drug monitoring market in the coming years. Drugs are substances used for medical purposes to diagnose, treat, or prevent diseases in humans or animals. Therapeutic drug monitoring helps optimize drug dosage by measuring and adjusting drug concentrations in the bloodstream, ensuring effectiveness while minimizing side effects. For example, in January 2024, the Office for Health Improvement & Disparities, a UK-based government department, reported that between April 2022 and March 2023, 12,418 young people under 18 engaged with alcohol and drug services, marking a 10% increase from 11,326 cases the previous year. Thus, the rising use of drugs is fueling growth in the therapeutic drug monitoring market.
Major companies in the therapeutic drug monitoring market are concentrating on developing anti-idiotypic antibody technology to improve the sensitivity and specificity of assays for accurately measuring biologic drug levels and evaluating patient immune responses. This technology is instrumental in therapeutic drug monitoring as it allows for precise detection and measurement of biologic drug levels, ensuring accurate dosing and effective tracking of patient immune responses. For example, in June 2024, Bio-Rad Laboratories, a U.S.-based biotechnology company, introduced new anti-idiotypic and anti-monomethyl auristatin E (MMAE) antibodies designed for bioanalytical assays, enhancing pharmacokinetic (PK) and antidrug-antibody (ADA) monitoring. These innovative antibodies improve the reliability of assays for antibody-drug conjugates (ADCs) and play a crucial role in the therapeutic drug monitoring market by enabling accurate assessments of drug levels and immune responses, ultimately facilitating optimal patient dosing.
In February 2023, Sentinel Diagnostics, an Italian in vitro diagnostic company, completed the acquisition of Eureka S.r.l. for an undisclosed amount. This strategic move positions Sentinel Diagnostics to emerge as a significant producer and developer of IVD tests. The expanded capabilities resulting from this acquisition will empower Sentinel Diagnostics to offer clinical laboratories a broader selection of assays, spanning from high-throughput core lab tests to the most cutting-edge, specialized second-level assays. EUREKA S.r.l. is an Italian IVD chromatographic company providing ready-to-use diagnostic kits for HPLC, GC, GC-MS, and LC-MS/MS applications, serving special clinical chemistry, therapeutic drug monitoring, occupational toxicology, and forensic toxicology purposes.
Major companies operating in the therapeutic drug monitoring market are Abbott Laboratories Inc., F. Hoffmann-La Roche AG, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Sekisui Medical Co., Buehlmann Laboratories AG, Danaher Corporation, Bio-Rad Laboratories Inc., bioMérieux SA, Randox Laboratories Limited, Chromsystems Instruments & Chemicals GmbH, Grifols SA, Merck KGaA, BioChem Pharmaceuticals, Beckman Coulter Inc., DiaSorin S.p.A., Hologic Inc., Immunodiagnostic Systems Holdings plc, Kronus Inc., QuidelOrtho Corporation, Sysmex Corporation, TDM Solutions Inc., Theradiag, Tosoh Bioscience LLC, Trinity Biotech plc, Associated Regional and University Pathologists Inc., Mayo Clinic Laboratories, Quest Diagnostics.
North America was the largest region in the therapeutic drug monitoring market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global therapeutic drug monitoring market report during the forecast period. The regions covered in the therapeutic drug monitoring market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the therapeutic drug monitoring market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the therapeutic drug monitoring market by increasing costs of imported analyzers, reagents, chromatography systems, mass spectrometers, and electronic components used in laboratory diagnostics. Hospital and commercial laboratories in North America and Europe are most affected due to reliance on imported analytical equipment, while Asia-Pacific faces higher costs for exported instruments. These tariffs are raising testing costs and slowing equipment upgrades. However, they are also encouraging local manufacturing, regional reagent production, and investment in domestic diagnostic capabilities.
The therapeutic drug monitoring market research report is one of a series of new reports that provides therapeutic drug monitoring market statistics, including therapeutic drug monitoring industry global market size, regional shares, competitors with a therapeutic drug monitoring market share, detailed therapeutic drug monitoring market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic drug monitoring industry. This therapeutic drug monitoring market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Therapeutic drug monitoring (TDM) is a clinical procedure that involves continuous monitoring of a patient's bloodstream to assess the concentration of a specific medicine, ensuring the effectiveness of their dose regimens. TDM is employed for pharmaceuticals that have challenging target concentrations to monitor, medications exhibiting significant pharmacokinetic variability, drugs with established therapeutic effects and notable side effects, and medications with narrow therapeutic ranges.
The primary product types within therapeutic drug monitoring encompass consumables, equipment, immunoassay analyzers, chromatography, and detectors. Consumables for therapeutic drug monitoring include reagents and supplies utilized alongside TDM assays. Various technologies are employed, such as immunoassays, chemiluminescence immunoassays, colorimetric immunoassays, fluorescence immunoassays, radioimmunoassay, other immunoassays, chromatography-ms, lc-ms, and gc-mc. These technologies cover different drug classes, including antiseptic drugs, antibiotic drugs, immunosuppressant drugs, antiarrhythmic drugs, bronchodilator drugs, psychoactive drugs, and other drugs. Therapeutic drug monitoring is applicable in diverse settings, including hospital laboratories, commercial and private laboratories, and other end-users.
The therapeutic drug monitoring market includes revenues earned by entities by providing drug monitoring, urine drug testing, drug efficacy testing, and drug toxicology. The market value includes the value of related goods sold by the service provider or included within the service offering. The therapeutic drug monitoring market also includes sales of Immunoassay kits, Mass spectrometry instruments, and Chromatography systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Therapeutic Drug Monitoring Market Characteristics
3. Therapeutic Drug Monitoring Market Supply Chain Analysis
4. Global Therapeutic Drug Monitoring Market Trends and Strategies
5. Therapeutic Drug Monitoring Market Analysis of End Use Industries
7. Global Therapeutic Drug Monitoring Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Therapeutic Drug Monitoring Total Addressable Market (TAM) Analysis for the Market
9. Therapeutic Drug Monitoring Market Segmentation
10. Therapeutic Drug Monitoring Market Regional and Country Analysis
11. Asia-Pacific Therapeutic Drug Monitoring Market
12. China Therapeutic Drug Monitoring Market
13. India Therapeutic Drug Monitoring Market
14. Japan Therapeutic Drug Monitoring Market
15. Australia Therapeutic Drug Monitoring Market
16. Indonesia Therapeutic Drug Monitoring Market
17. South Korea Therapeutic Drug Monitoring Market
18. Taiwan Therapeutic Drug Monitoring Market
19. South East Asia Therapeutic Drug Monitoring Market
20. Western Europe Therapeutic Drug Monitoring Market
21. UK Therapeutic Drug Monitoring Market
22. Germany Therapeutic Drug Monitoring Market
23. France Therapeutic Drug Monitoring Market
24. Italy Therapeutic Drug Monitoring Market
25. Spain Therapeutic Drug Monitoring Market
26. Eastern Europe Therapeutic Drug Monitoring Market
27. Russia Therapeutic Drug Monitoring Market
28. North America Therapeutic Drug Monitoring Market
29. USA Therapeutic Drug Monitoring Market
30. Canada Therapeutic Drug Monitoring Market
31. South America Therapeutic Drug Monitoring Market
32. Brazil Therapeutic Drug Monitoring Market
33. Middle East Therapeutic Drug Monitoring Market
34. Africa Therapeutic Drug Monitoring Market
36. Therapeutic Drug Monitoring Market Competitive Landscape and Company Profiles
37. Therapeutic Drug Monitoring Market Other Major and Innovative Companies
40. Therapeutic Drug Monitoring Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Therapeutic Drug Monitoring Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses therapeutic drug monitoring market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for therapeutic drug monitoring? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The therapeutic drug monitoring market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Consumables; Equipment; Immunoassay Analyzers; Chromatography And Detectors2) By Class Of Drug: Antiepileptic Drugs; Antibiotic Drugs; Immunosuppressant Drugs; Antiarrhythmic Drugs; Psychoactive Drugs; Other Drugs
3) By End-user: Hospital Laboratories; Commercial and Private Laboratories; Other End Users
Subsegments:
1) By Consumables: Reagents; Test Kits; Sample Collection Containers; Calibration Standards2) By Equipment: Analyzers; Incubators; Centrifuges
3) By Immunoassay Analyzers: ELISA Analyzers; Chemiluminescent Immunoassay Analyzers; Radioimmunoassay Analyzers
4) By Chromatography And Detectors: High-Performance Liquid Chromatography (HPLC); Gas Chromatography (GC); Mass Spectrometry (MS)
Companies Mentioned: Abbott Laboratories Inc.; F. Hoffmann-La Roche AG; Siemens Healthineers AG; Thermo Fisher Scientific Inc.; Sekisui Medical Co.; Buehlmann Laboratories AG; Danaher Corporation; Bio-Rad Laboratories Inc.; bioMérieux SA; Randox Laboratories Limited; Chromsystems Instruments & Chemicals GmbH; Grifols SA; Merck KGaA; BioChem Pharmaceuticals; Beckman Coulter Inc.; DiaSorin S.p.A.; Hologic Inc.; Immunodiagnostic Systems Holdings plc; Kronus Inc.; QuidelOrtho Corporation; Sysmex Corporation; TDM Solutions Inc.; Theradiag; Tosoh Bioscience LLC; Trinity Biotech plc; Associated Regional and University Pathologists Inc.; Mayo Clinic Laboratories; Quest Diagnostics
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Therapeutic Drug Monitoring market report include:- Abbott Laboratories Inc.
- F. Hoffmann-La Roche AG
- Siemens Healthineers AG
- Thermo Fisher Scientific Inc.
- Sekisui Medical Co.
- Buehlmann Laboratories AG
- Danaher Corporation
- Bio-Rad Laboratories Inc.
- bioMérieux SA
- Randox Laboratories Limited
- Chromsystems Instruments & Chemicals GmbH
- Grifols SA
- Merck KGaA
- BioChem Pharmaceuticals
- Beckman Coulter Inc.
- DiaSorin S.p.A.
- Hologic Inc.
- Immunodiagnostic Systems Holdings plc
- Kronus Inc.
- QuidelOrtho Corporation
- Sysmex Corporation
- TDM Solutions Inc.
- Theradiag
- Tosoh Bioscience LLC
- Trinity Biotech plc
- Associated Regional and University Pathologists Inc.
- Mayo Clinic Laboratories
- Quest Diagnostics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.67 Billion |
| Forecasted Market Value ( USD | $ 4.09 Billion |
| Compound Annual Growth Rate | 11.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
